Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peptic Ulcer

Peptic Ulcer

Peptic ulcers are erosive lesions of the gastric or duodenal lining, most commonly caused by Helicobacter pylori infection. This Gram-negative, helical bacterium has adapted to survive the stomach’s acidic environment by producing urease, which converts urea into ammonia and carbon dioxide. The ammonia neutralizes gastric acid in the bacterium’s immediate environment, allowing colonization of the gastric mucosa. H. pylori attaches to mucus-secreting epithelial cells, penetrates the mucus...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lung regulatory T cells and inflammatory mediators associate with heterogeneous outcomes in a SARS-CoV-2 infected mouse model.

Japanese journal of infectious diseases·2026

Same author

Human peritoneal CCR2<sup>Low</sup>CRIg<sup>High</sup> macrophage subset exhibits embryonic origin-like phenotypes.

Human cell·2026

Same author

Dynamics of lung-infiltrating virus-specific T cells associated with age-dependent SARS-CoV-2 pneumonia severity.

PLoS pathogens·2026

Same author

A BRIEF HISTORY OF BELGIAN IMMUNOLOGY AND ITS SOCIETY.

European journal of immunology·2022

Same author

Pertussis seroprevalence among adults of reproductive age (20-39 years) in fourteen European countries.

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica·2021

Same author

Alfalfa Plants (Medicago sativa L.) Expressing the 85B (MAP1609c) Antigen of Mycobacterium avium subsp. paratuberculosis Elicit Long-Lasting Immunity in Mice.

Molecular biotechnology·2021

Search research articles

Related Experiment Videos

Buruli ulcer.

Thorbjorg Einarsdottir¹, Kris Huygen

¹WIV-ISP Site Ukkel, Service Immunology, Brussels, Belgium.

|November 4, 2011

Summary

Buruli ulcer (BU) is a severe skin disease caused by M. ulcerans. This review explores potential vaccine targets and methods to combat BU, addressing knowledge gaps in the bacterium and immune response.

Area of Science:

Microbiology
Immunology
Tropical Diseases

Background:

Buruli ulcer (BU) is a neglected, necrotizing skin disease caused by Mycobacterium ulcerans.
The disease leads to significant scarring and lifelong disability.
Mycolactone, a toxin produced by M. ulcerans, is crucial for virulence, but disease transmission remains poorly understood, hindering prevention and vaccine development.

Purpose of the Study:

To review current understanding of M. ulcerans vaccine targets.
To discuss various vaccination methods for Buruli ulcer.
To identify knowledge gaps regarding the bacterium and host immune responses.

Main Methods:

Review of recent advances in M. ulcerans research.
Analysis of bacterial genome and plasmid sequencing data.

Related Experiment Videos

Examination of mycolactone synthesis and mechanism of action.

Main Results:

Identification of potential vaccine candidates, some shared with other mycobacteria.
Understanding of the bacterial lifecycle and toxin's action.
Highlighting of M. ulcerans-specific vaccine targets.

Conclusions:

Recent genomic and mechanistic studies offer promising vaccine avenues.
Further research is needed to understand the bacterium and immune response for effective Buruli ulcer prevention.
Addressing knowledge gaps is critical for developing a Buruli ulcer vaccine.